Treating conditions associated with increased eotaxin with 25-hydroxyvitamin D3
US10357501B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2016 |
| Grant date | Jul 23, 2019 |
| Priority date | — |
| Expiry date | Jan 9, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2002/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.